Stay updated on Acalabrutinib vs Ibrutinib in CLL Clinical Trial
Sign up to get notified when there's something new on the Acalabrutinib vs Ibrutinib in CLL Clinical Trial page.

Latest updates to the Acalabrutinib vs Ibrutinib in CLL Clinical Trial page
- Check2 days agoChange DetectedNIH grant/contract attributions for 2023 and 2014 were added to the study record, and the revision tag was updated to v3.6.6, reflecting a metadata update.SummaryDifference0.2%

- Check9 days agoNo Change Detected
- Check15 days agoNo Change Detected
- Check22 days agoChange DetectedRevision tag updated from v3.6.4 to v3.6.5, signaling a small update to the page's version or content.SummaryDifference0.0%

- Check37 days agoChange DetectedThe revision of the page was updated from v3.6.3 to v3.6.4, indicating a small patch to the document's revision metadata.SummaryDifference0.0%

- Check58 days agoChange DetectedThe page’s revision indicator was updated to v3.6.3, signaling a version update; this does not modify the study details themselves.SummaryDifference0.0%

- Check66 days agoChange DetectedThe page’s revision label was updated from v3.6.0 to v3.6.2, signaling a new version in the revision history rather than a modification to the study content.SummaryDifference0.0%

- Check80 days agoChange DetectedThe page now shows recruitment as no longer looking for participants, and new user guidance sections (How to Read a Study Record, Common Questions, How to Join a Study) were added. A formatting change updates the Intervention label from 'Intervention / Treatment' to 'Intervention/Treatment' and the revision tag to v3.6.0.SummaryDifference0.2%

Stay in the know with updates to Acalabrutinib vs Ibrutinib in CLL Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Acalabrutinib vs Ibrutinib in CLL Clinical Trial page.